Edoxaban is a selective factor‐Xa (FXa) inhibitor for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF).1, 2, 3 Since 2021, edoxaban 15 mg dose has been approved in Japan as a new dose for very elderly patients with high bleeding risks. The gene discussed is F10; the disease is stroke disorder.